(ABM FN-Dow Jones) The European Commission has approved filgotinib for the treatment of adult patients with moderately to severely active ulcerative colitis. Galapagos reported this on Monday afternoon.
“We are very pleased that the European Commission has approved Jyseleca as a treatment for people suffering from UC. This decision supports the efficacy and safety profile of Jyseleca, which, to date, has been studied in more than 1,250 patients with UC,” said CEO Onno van de Stolpe in an explanation.
“Our focus is now on making this treatment available to physicians and patients with UC across the European Union as quickly as possible,” said the Galapagos chief executive.
Jyseleca, the brand name of filgotinib, was previously approved in Europe as a treatment for rheumatism. Jyseleca may also be sold as a rheumatoid arthritis medicine in Japan. In the United States, approval for the anti-inflammatory drug as a treatment for both rheumatism and UC seems rather small, because the FDA has safety concerns.
Galapagos shares rose almost 2 percent after the news.
Bron: ABM Financial News
From Beursplein 5, the editors of ABM Financial News keep a close eye on developments on the stock exchanges, and the Amsterdam stock exchange in particular. The information in this column is not intended as professional investment advice or as a recommendation to make certain investments.
–
